Caplacizumab
- CAS No.
- 915810-67-2
- Chemical Name:
- Caplacizumab
- Synonyms
- Caplacizumab;Research Grade Caplacizumab;Research Grade Caplacizumab(DHC08501)
- CBNumber:
- CB58080847
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Caplacizumab | CLA1289 | 1mg | $687.5 |
| Caplacizumab | CLA1289 | 5mg | $1718.75 |
| Caplacizumab | CLA1289 | 10mg | $2475 |
| Caplacizumab His Tag ≥99.0% | CS-0612702 | 1mg | $303 |
| Caplacizumab His Tag ≥99.0% | CS-0612702 | 5mg | $758 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 2R27AB6766 |
| ATC code | B01AX07 |
Caplacizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | CLA1289 | Caplacizumab | 915810-67-2 | 1mg | $687.5 | 2026-06-04 | Buy |
| Biosynth | CLA1289 | Caplacizumab | 915810-67-2 | 5mg | $1718.75 | 2026-06-04 | Buy |
| Biosynth | CLA1289 | Caplacizumab | 915810-67-2 | 10mg | $2475 | 2026-06-04 | Buy |
| ChemScene | CS-0612702 | Caplacizumab His Tag ≥99.0% | 915810-67-2 | 1mg | $303 | 2026-06-04 | Buy |
| ChemScene | CS-0612702 | Caplacizumab His Tag ≥99.0% | 915810-67-2 | 5mg | $758 | 2026-06-04 | Buy |
Caplacizumab Chemical Properties,Uses,Production
Uses
Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP)[1][2][3][4].
in vivo
Caplacizumab (2.5 mg/kg, s.c., daily, from day 1 to day 5 for preventive group) completely prevents the rapid onset of severe thrombocytopenia and schistocytic hemolytic anemia in a baboon model of acquired thrombotic thrombocytopenic purpura, and promotes the recovery of platelet counts after induction of TTP[3].
Caplacizumab (at plasma levels between 0.3-0.5 μg/mL, i.v. bolus) shows a strong antithrombotic effect in a modified Folts model in baboons[4].
Caplacizumab (5 mg/kg total dose with intravenous and subcutaneous injection; intravenous injection first and subcutaneous injections follow) prevents middle cerebral artery thrombosis in a guinea pig model of middle cerebral artery thrombosis, and reduces brain damage without inducing hemorrhage[5].
| Animal Model: | Guinea pig (Dunkin-Hartley, male, 350-400 g) model of middle cerebral artery thrombosis[5] |
| Dosage: | 5 mg/kg total dose (0.4 mg/kg intravenously + 1.6 mg/kg subcutaneously at time 0 followed by 3 mg/kg subcutaneously 6 h later) |
| Administration: | Intravenous injection first and subcutaneous injections follow |
| Result: | Prevented thrombosis when administered immediately after and 15 min after complete occlusion of the middle cerebral artery. Reduced brain damage area and did not increase intracerebral hemorrhage. Reduced microvascular thrombosis in the ischemic brain tissue. |
References
[1] Malle le Besnerais, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. DOI:10.1080/14712598.2019.1650908
[2] Nakayama M, et al. Effects of caplacizumab, a specific inhibitor of the A1 domain of von Willebrand factor binding with platelet membrane glycoprotein (GP) Ibα, on the length of platelet pseudopods supporting platelet adhesions on immobilized von Willebrand factor under blood flow condition. Journal of Biorheology, 2022, 36(2): 68-75.
[3] Callewaert F, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 Oct 25;120(17):3603-10. DOI:10.1182/blood-2012-04-420943
[4] Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65. DOI:10.1182/blood-2010-11-317859
[5] Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013 Jun 20;121(25):5088-97. DOI:10.1182/blood-2012-11-464545
Caplacizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Caplacizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19936 | 58 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Beijing Solarbio Science & Tecnology Co., Ltd. | 17801761073 18101056239 | 3193328036@qq.com | China | 29660 | 68 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9865 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7101 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11972 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4590 | 58 |
| Shanghai?Medlife?Pharm-Tech?Co.,?Ltd | 4000862158 18117107507 | vip@med-life.cn | China | 5001 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5434 | 58 |
